The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination

Despite extensive preclinical evidence that peroxisome proliferator-activated receptor (PPAR)γ activation protects against tumourigenesis, results from a few clinical trials using PPARγ ligands as monotherapy show modest success. In spite of this, several groups reported exciting results with therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Skelhorne-Gross, Graham, Nicol, Christopher J. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395155/
https://www.ncbi.nlm.nih.gov/pubmed/22966225
http://dx.doi.org/10.1155/2012/946943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395155/
https://www.ncbi.nlm.nih.gov/pubmed/22966225
http://dx.doi.org/10.1155/2012/946943

Ejemplares similares